TEBIPENEM PIVOXIL HYDROCHLORIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C22H31N3O6S2.ClH
Molecular Weight	534.089
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of TEBIPENEM PIVOXIL HYDROCHLORIDE

Structure Search

SMILES

Cl.C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C4=NCCS4)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C

InChI

InChIKey=ZXGTYOBSVQZXSC-HXLQFWNVSA-N

InChI=1S/C22H31N3O6S2.ClH/c1-11-15-14(12(2)26)18(27)25(15)16(19(28)30-10-31-20(29)22(3,4)5)17(11)33-13-8-24(9-13)21-23-6-7-32-21;/h11-15,26H,6-10H2,1-5H3;1H/t11-,12-,14-,15-;/m1./s1

HIDE SMILES / InChI

Molecular Formula	C22H31N3O6S2
Molecular Weight	497.628
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=2372 | https://www.ncbi.nlm.nih.gov/pubmed/26751436

Tebipenem pivoxil is an oral carbapenem prodrug that was originated by Wyeth (now Pfizer). It was approved by Pharmaceuticals and Medical Devices Agency of Japan (PMDA) on Apr 22, 2009. It was developed and marketed as Orapenem® by Meiji Seika in Japan. Tebipenem pivoxil is a broad-spectrum orally-administered antibiotic, from the carbapenem subgroup of β-lactam antibiotics. Carbapenems are a class of beta-lactam antibiotics, which act by inhibiting the synthesis of the peptidoglycan layer of bacterial cell walls. It is used to treat otorhinolaryngological infection, otitis media and bacterial pneumonia. Orapenem® is available as granules for oral use, containing 100 mg Tebipenem pivoxil/g granules. According to the weight of children, 4 mg/kg, and twice a day after dinner.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Penicillin-binding protein 31 Target ID: CHEMBL2362973 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15728880 \| https://www.ncbi.nlm.nih.gov/pubmed/26751436	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Otitis media 42 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=2372 http://adisinsight.springer.com/drugs/800010812	Curative	Approved 8583	ORAPENEM Approved Use Orapenem is usually used to treat pneumonia, otitis media and sinusitis. Launch Date 2009
Pneumonia 91 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=2372 http://adisinsight.springer.com/drugs/800010812	Curative	Approved 8583	ORAPENEM Approved Use Orapenem is usually used to treat pneumonia, otitis media and sinusitis. Launch Date 2009
Sinusitis 26 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=2372 http://adisinsight.springer.com/drugs/800010812	Curative	Approved 8583	ORAPENEM Approved Use Orapenem is usually used to treat pneumonia, otitis media and sinusitis. Launch Date 2009

C_max

Value	Dose	Analyte	Population
11.81 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30903927/	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
3.9 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30903927/	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT
6087.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34326771/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
11099.17 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34326771/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
17825 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34326771/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
256 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1209 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1944 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2943 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	900 mg single, oral dose: 900 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4062 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3064 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
6216 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1810 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2893 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4006 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
6203 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
12652 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	900 mg single, oral dose: 900 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1892 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
3014 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
1852 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
1677 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
5830 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
2288 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
2058 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
6451 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
7759 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	300 mg 3 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
13428 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	600 mg 3 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
6493 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	300 mg 3 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
15090 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	600 mg 3 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.71 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19673356/ \| http://journal.chemotherapy.or.jp/detail_e.php?-DB=jsc&-recid=4826&-action=browse	100 mg 3 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
6.08 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19673356/ \| http://journal.chemotherapy.or.jp/detail_e.php?-DB=jsc&-recid=4826&-action=browse	200 mg 3 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
4.74 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19673356/ \| http://journal.chemotherapy.or.jp/detail_e.php?-DB=jsc&-recid=4826&-action=browse	300 mg 3 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
5.08 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19673356/	150 mg 3 times / day multiple, oral dose: 150 mg route of administration: Oral experiment type: MULTIPLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
7.92 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19673356/	250 mg 2 times / day multiple, oral dose: 250 mg route of administration: Oral experiment type: MULTIPLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
8.69 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19673356/	300 mg 3 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
9.85 μg/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900019/78000900_22100AMX00643_A100_1.pdf#page=45 \| https://www.pmda.go.jp/drugs/2009/P200900019/78000900_22100AMX00643_K101_1.pdf#page=24	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
7.17 μg/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900019/78000900_22100AMX00643_A100_1.pdf#page=45 \| https://www.pmda.go.jp/drugs/2009/P200900019/78000900_22100AMX00643_K101_1.pdf#page=24	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
13.26 μg/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900019/78000900_22100AMX00643_A100_1.pdf#page=45 \| https://www.pmda.go.jp/drugs/2009/P200900019/78000900_22100AMX00643_K101_1.pdf#page=24	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
13.88 μg/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900019/78000900_22100AMX00643_A100_1.pdf#page=45 \| https://www.pmda.go.jp/drugs/2009/P200900019/78000900_22100AMX00643_K101_1.pdf#page=24	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
10.46 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30903927/	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
9.52 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30903927/	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT
6407.34 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34326771/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
12517.7 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34326771/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
23126.57 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34326771/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
872 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3738 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
5192 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
10571 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	900 mg single, oral dose: 900 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
7268 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
6267 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
13602 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4456 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2875 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
6488 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
12715 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
21913 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	900 mg single, oral dose: 900 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
7175 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
14727 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
6215 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
6549 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
16547 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
6579 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
6137 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
14200 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
7726 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	300 mg 3 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
20592 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	600 mg 3 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
7484 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	300 mg 3 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
17924 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	600 mg 3 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3.2 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19673356/ \| http://journal.chemotherapy.or.jp/detail_e.php?-DB=jsc&-recid=4826&-action=browse	100 mg 3 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
6.68 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19673356/ \| http://journal.chemotherapy.or.jp/detail_e.php?-DB=jsc&-recid=4826&-action=browse	200 mg 3 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
11.35 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19673356/ \| http://journal.chemotherapy.or.jp/detail_e.php?-DB=jsc&-recid=4826&-action=browse	300 mg 3 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
5.22 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19673356/	150 mg 3 times / day multiple, oral dose: 150 mg route of administration: Oral experiment type: MULTIPLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
7.93 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19673356/	250 mg 2 times / day multiple, oral dose: 250 mg route of administration: Oral experiment type: MULTIPLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
13.62 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19673356/	300 mg 3 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
12.29 μg × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900019/78000900_22100AMX00643_A100_1.pdf#page=45 \| https://www.pmda.go.jp/drugs/2009/P200900019/78000900_22100AMX00643_K101_1.pdf#page=24	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
16.45 μg × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900019/78000900_22100AMX00643_A100_1.pdf#page=45 \| https://www.pmda.go.jp/drugs/2009/P200900019/78000900_22100AMX00643_K101_1.pdf#page=24	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
29.22 μg × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900019/78000900_22100AMX00643_A100_1.pdf#page=45 \| https://www.pmda.go.jp/drugs/2009/P200900019/78000900_22100AMX00643_K101_1.pdf#page=24	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
92.59 μg × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900019/78000900_22100AMX00643_A100_1.pdf#page=45 \| https://www.pmda.go.jp/drugs/2009/P200900019/78000900_22100AMX00643_K101_1.pdf#page=24	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
0.77 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30903927/	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.91 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30903927/	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT
0.84 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34326771/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.76 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34326771/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.92 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/34326771/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	900 mg single, oral dose: 900 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	900 mg single, oral dose: 900 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
1.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
0.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
1.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
0.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
0.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
0.82 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	300 mg 3 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.79 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	600 mg 3 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.72 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	300 mg 3 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.83 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31262768/	600 mg 3 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.44 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19673356/ \| http://journal.chemotherapy.or.jp/detail_e.php?-DB=jsc&-recid=4826&-action=browse	100 mg 3 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
0.36 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19673356/ \| http://journal.chemotherapy.or.jp/detail_e.php?-DB=jsc&-recid=4826&-action=browse	200 mg 3 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
0.67 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19673356/ \| http://journal.chemotherapy.or.jp/detail_e.php?-DB=jsc&-recid=4826&-action=browse	300 mg 3 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
0.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19673356/	150 mg 3 times / day multiple, oral dose: 150 mg route of administration: Oral experiment type: MULTIPLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
0.34 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19673356/	250 mg 2 times / day multiple, oral dose: 250 mg route of administration: Oral experiment type: MULTIPLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
0.54 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19673356/	300 mg 3 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
0.88 h OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900019/78000900_22100AMX00643_A100_1.pdf#page=45 \| https://www.pmda.go.jp/drugs/2009/P200900019/78000900_22100AMX00643_K101_1.pdf#page=24	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.49 h OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900019/78000900_22100AMX00643_A100_1.pdf#page=45 \| https://www.pmda.go.jp/drugs/2009/P200900019/78000900_22100AMX00643_K101_1.pdf#page=24	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.44 h OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900019/78000900_22100AMX00643_A100_1.pdf#page=45 \| https://www.pmda.go.jp/drugs/2009/P200900019/78000900_22100AMX00643_K101_1.pdf#page=24	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.11 h OTHER GOV'T https://www.pmda.go.jp/drugs/2009/P200900019/78000900_22100AMX00643_A100_1.pdf#page=45 \| https://www.pmda.go.jp/drugs/2009/P200900019/78000900_22100AMX00643_K101_1.pdf#page=24	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	TEBIPENEM plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
26.1% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19882982/			TEBIPENEM serum	Homo sapiens

PubMed

Title	Date	PubMed
[Convulsive liability of an oral carbapenem antibiotic, tebipenem pivoxil].	2009-06	19882983
Syntheses and pharmacokinetic studies of prodrug esters for the development of oral carbapenem, L-084.	2006-04	16830892

Patents

Sample Use Guides

In Vivo Use Guide

For children: In general, take 0.04 gram per kilogram of body weight (g/kg) (4 mg of the active ingredient [titer]/kg) at a time, twice a day, after meals. The dosage may be increased up to 0.06 g/kg (6 mg [titer]/kg) as needed. Strictly follow the instructions. Standard duration of administration is for 7 days or less. If you miss a dose, take a dose as soon as possible. However, if it is almost time for the next dose, skip the missed dose and follow your regular dosing schedule. You should never take two doses at one time.

Route of Administration: Oral

In Vitro Use Guide

The MIC90 values of tebipenem pivoxil against Gram-positive bacteria such as methicillin-sensitive Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA), methicillin-sensitive Staphylococcus epidermidis (MSSE), methicillin-resistant Staphylococcus epidermidis (MRSE), Pyogenic streptococcus, and Enterococcus faecalis were ≤ 0.125, 16, 0.5, 8, ≤ 0.125, and 32 ug/mL, respectively. Correspondingly, the MIC90 values of tebipenem pivoxil against Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Haemophilus influenzae, Pseudomonas aeruginosa, and Acinetobacter baumannii were 1, 0.5, ≤ 0.125, 0.25, 64, 64 ug/mL, respectively. The MBC values of tebipenem pivoxil against Escherichia coli, Staphylococcus aureus, Klebsiella pneumoniae were 0.016-2, 0.063-32, 0.031-32 ug/mL, respectively.

Substance Class	Chemical Created by `admin` on `Wed Apr 02 01:27:15 GMT 2025` Edited by `admin` on `Wed Apr 02 01:27:15 GMT 2025`
Record UNII	0Z7A0FSA63
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

1-AZABICYCLO(3.2.0)HEPT-2-ENE-2-CARBOXYLIC ACID, 3-((1-(4,5-DIHYDRO-2-THIAZOLYL)-3-AZETIDINYL)THIO)-6-((1R)-1-HYDROXYETHYL)-4-METHYL-7-OXO-, (2,2-DIMETHYL-1-OXOPROPOXY)METHYL ESTER, HYDROCHLORIDE (1:1), (4R,5S,6S)-

Preferred Name

English

TEBIPENEM PIVOXIL HYDROCHLORIDE

Common Name

English

1-AZABICYCLO(3.2.0)HEPT-2-ENE-2-CARBOXYLIC ACID, 3-((1-(4,5-DIHYDRO-2-THIAZOLYL)-3-AZETIDINYL)THIO)-6-((1R)-1-HYDROXYETHYL)-4-METHYL-7-OXO-, (2,2-DIMETHYL-1-OXOPROPOXY)METHYL ESTER, MONOHYDROCHLORIDE, (4R,5S,6S)-

Systematic Name

English

Code System Code Type Description

PUBCHEM

71623820

Created by admin on Wed Apr 02 01:27:15 GMT 2025 , Edited by admin on Wed Apr 02 01:27:15 GMT 2025

PRIMARY

CAS

211558-19-9

Created by admin on Wed Apr 02 01:27:15 GMT 2025 , Edited by admin on Wed Apr 02 01:27:15 GMT 2025

PRIMARY

FDA UNII

0Z7A0FSA63

Created by admin on Wed Apr 02 01:27:15 GMT 2025 , Edited by admin on Wed Apr 02 01:27:15 GMT 2025

PRIMARY

Related Record Type Details


					95AK1A52I8

TEBIPENEM PIVOXIL

PARENT -> SALT/SOLVATE

Amount:

Details

SMILES

InChI

DescriptionSources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=2372 | https://www.ncbi.nlm.nih.gov/pubmed/26751436

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Cmax

AUC

T1/2

Funbound

PubMed

Patents

Sample Use Guides

Description
Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=2372 | https://www.ncbi.nlm.nih.gov/pubmed/26751436

C_max

T_1/2

F_unbound